THESE NEW MEDICATONS ARE JUST THE BEGINNING
that is me getting an infusion of aduhelm at ucla as part of the embark clinical trial at ucla
aduhelm is approved by the fda for use in mci or early alzheimers
medicare will only pay for it if its given in a clinical trial
once it gets full approval by the fda medicare will probably give its full approval to pay for it
my study and other studies will be finished soon and will be reported out
if it shows that it improves or slows down cognitive decline it will probably get full approval
the problem was that biogen didnt finish the studies that needed to be done before they sought approval
more than likely in the future aduhelm will be the third choice behind leqembi and donanemab
all 3 grab amyloid or amyloid plaques and remove them
all 3 will show that they slow down cognitive decline
leqembi just got full approval
its given every two weeks in an infusion like im getting above
it is being studied to be given as a shot like insulin is given so folks can give it at home
much like humira is given at home for rheumatoid arthritis
that will make leqembi attractive for use since it eliminates the hassle of going to an infusion center
the infrastructure for giving these drugs is a major obstacle to receiving it
at home shots eliminate this major problem
donanemab will probably get full approval later this year
medicare will probably give its full approval to pay for it also
donanemab seems to work better than the other two
when given to real early folks like me who have mci or mild alzheimers
the cognitive decline was slowed by about 67%+-
it is given as a monthly infusion
donanemab seems to have more side effects than the other two
it also doesnt have to be given as long as the others have to be given
the side effects are aria or amyloid related imaging abnormalities
aria e means with edema
aria h means with hemorrhage
bot of these can be seen on mri
all my mris show no aria after 32 infusions of aduhelm
if you have the apoe 4 gene you are at increased risk for these aria
if you have two copies of the apoe 4 genes or homozygous apoe 4 your risk is even higher
i am homozygous apoe 4 but had no aria
2 folks died in the donanemab study from aria
both were put on blood thinners for other reasons
several other folks on the study were placed on blood thinners and had no issue
dr daniel gibbs from a tattoo on my brain was in the aduhelm study and had a major bleed
he was not allowed back in the study
he can not receive any of these drugs again
most folks in these studies who developed aria e or aria h on mris had no symptoms
the aria e and aria h resolved
so what to expect if you want to get on these drugs
there are strict criteria
you must have mci or mild cognitive impairment or early alzheimers symptoms
not early onset alzheimers as thats a different genetic version that hits younger folks
you have to see a doctor who has done a good through workup to include a history and physical and labs and good through memory tests
you have to have an apoe 4 genetic test since if you have this you are at a higher risk for the aria h bleeds
you if you are positive have to have counseling regards the risk
i was positive
i was counseled
i without hesitation said go for it i want this drug
i accepted the risk knowing there was not another choice for treatment
i saw a neurologists this week who said you know you are an interesting case
you should not be doing this well
you have an mri
then
if its looking like alzheimers you either have to have a spinal tap for amyloid and tau or you have to have a amyloid pet scan for amyloid
medicare will probably approve paying for these tests
if they are a positive you are a good candidate to receive this drug
it does not work in folks who have moderate alzheimers or severe alzheimers or the genetic early onset alzheimers or in early alzheimers if you have a high tau tangle level on a tau pet scan
if you do get approved you have to have the infusions at a infusion center
the first one you have to stay there for 2-3 hours to make sure you have no reaction
the infusion itself takes about an hour
leqembi is setting up infusion centers across the usa so more folks can get them
some think a tau pet scan also needs to be done since if the tau levels are real high in the brain then these drugs wont work as well
right now these arent required
research is trying to decide how long to treat with these drugs then how often to do maintenance dosing
remember these drugs remove almost if not all amyloid plaques from the brain
the amyloid though is continuously being deposited into plaques so the meds have to be given regularly to keep the amyloid plaques from being reformed
so it probably means a lifetime of getting these infusions
for me
i will finish my embark study in one year
i will then decide which way to go
im leaning towards leqembi by injections at home when they become available
other results from all these studies though may alter that decision
also
a new pill that removes amyloid and keeps the plaques from forming is being studied now
its expected to get approval in about 2 years
that sounds good to me
then
right after that will be a medication to remove the tau tangles from the brain
so
eventually probably ill take a pill to prevent the amyloid from forming new plaques
then take infusions to remove the tau
then
when a new drug to treat the inflammation in the brain becomes available ill take that one
these new drugs the antiamyloid antibody drugs like aduhelm or leqembi or donanemab have opened the door to even newer drugs to treat this disease
next also
they will probably start treating folks who have the amyloid plaques in the brain with no symptoms
this will be diagnosed initially via a blood test in your primary care office
then
you can then start one of these new drugs plus do all the healthy things one should be doing
the goal
you wont ever develop alzheimers disease
for me
i am so early in my disease earlier than most so i have benefited most form these treatments
i like being an interesting case
these are exciting times in the alzheimers world
the organicgreen doctor
No comments:
Post a Comment